Atypical Femoral Fractures and Bone Turnover
Authors:
- Sophie A. JamalSJSophie A. Jamal
- Natalie DionNDNatalie Dion
- Louis-Georges Ste-MarieLSLouis-Georges Ste-Marie
- 29 September 2011
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (13) , 1261-1262
Abstract
Epidemiologic studies and case series and reports suggest that there is a relation between the long-term use of bisphosphonates and the development of atypical femoral fractures.1 Although the cause of such fractures is unknown, the fact that bisphosphonates decrease bone resorption and formation and also have a long half-life in bone has led to the common belief that atypical fractures associated with bisphosphonate use are due to the marked suppression of bone turnover, resulting in the accumulation of microdamage that can lead to fractures.Keywords
This publication has 4 references indexed in Scilit:
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research, 2010
- Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long-Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone FragilityJournal of Bone and Mineral Research, 2009
- Effects of Continuing or Stopping Alendronate After 5 Years of TreatmentJAMA, 2006
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004